Difference between revisions of "Stub"
Warner-admin (talk | contribs) m (Text replacement - "Folinic acid (Leucovorin)" to "Leucovorin (Folinic acid)") |
|||
Line 165: | Line 165: | ||
*[[Methotrexate (MTX)]] | *[[Methotrexate (MTX)]] | ||
====Supportive therapy==== | ====Supportive therapy==== | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
==Binimetinib monotherapy== | ==Binimetinib monotherapy== | ||
Line 753: | Line 753: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Etoposide (Vepesid)]] | *[[Etoposide (Vepesid)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
Line 880: | Line 880: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Cetuximab (Erbitux)]] | *[[Cetuximab (Erbitux)]] | ||
Line 891: | Line 891: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
*[[Irinotecan (Camptosar)]] | *[[Irinotecan (Camptosar)]] | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
Line 902: | Line 902: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
*[[Irinotecan (Camptosar)]] | *[[Irinotecan (Camptosar)]] | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
Line 913: | Line 913: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
*[[Irinotecan (Camptosar)]] | *[[Irinotecan (Camptosar)]] | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
Line 924: | Line 924: | ||
*[[Cisplatin (Platinol)]] | *[[Cisplatin (Platinol)]] | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
==FULV & Edrecolomab== | ==FULV & Edrecolomab== | ||
Line 931: | Line 931: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Edrecolomab (Panorex)]] | *[[Edrecolomab (Panorex)]] | ||
Line 940: | Line 940: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Interferon alfa-2a (Roferon-A)]] | *[[Interferon alfa-2a (Roferon-A)]] | ||
Line 949: | Line 949: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Interferon alfa-2b (Intron-A)]] | *[[Interferon alfa-2b (Intron-A)]] | ||
Line 958: | Line 958: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Interferon alfa-2c (Berofor)]] | *[[Interferon alfa-2c (Berofor)]] | ||
Line 968: | Line 968: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
*[[Trimetrexate (Neutrexin)]] | *[[Trimetrexate (Neutrexin)]] | ||
Line 1,025: | Line 1,025: | ||
*[[Semustine (MeCCNU)]] | *[[Semustine (MeCCNU)]] | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
==MFT== | ==MFT== | ||
Line 1,155: | Line 1,155: | ||
*[[Cisplatin (Platinol)]] | *[[Cisplatin (Platinol)]] | ||
*[[Epirubicin (Ellence)]] | *[[Epirubicin (Ellence)]] | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] |
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
Revision as of 15:34, 29 September 2023
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the HemOnc Ontology and for historic interest.
Regimens composed solely of approved drugs
3M
3M: Mitomycin, Mitoxantrone, Methotrexate
Regimen
Chemotherapy
5-FU & RT
Regimen
Chemotherapy
Radiotherapy
- Concurrent radiation therapy
7+3i & Clofarabine
7+3i & Clofarabine: 7 days of cytarabine, 3 days of idarubicin, Clofarabine
Regimen
Chemotherapy
7+3i & Lenalidomide
7+3i & Lenalidomide: 7 days of cytarabine, 3 days of idarubicin, Lenalidomide
Regimen
Chemotherapy
Targeted therapy
7+4i
7+4i: 7 days of cytarabine, 4 days of idarubicin
Regimen
Chemotherapy
7+5d
7+5d: 7 days of cytarabine, 5 days of daunorubicin
Regimen
Chemotherapy
Abiraterone & Enzalutamide
Regimen
Endocrine therapy
ABV
ABV: Adriamycin (Doxorubicin), Bleomycin, Vinblastine
Regimen
Chemotherapy
ABVP
ABVP: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Platinol (Cisplatin)
Regimen
Chemotherapy
ACP
ACP: Atezolizumab, Carboplatin, Paclitaxel
Regimen
Immunotherapy
Chemotherapy
Afatinib & Vinorelbine
Regimen
Chemotherapy
Targeted therapy
A-ICE
A-ICE: ATRA, Idarubicin, Cytarabine, Etoposide
Regimen
Targeted therapy
Chemotherapy
AME
AME: Ara-C (Cytarabine), Mitoxantrone, Etoposide
Regimen
Chemotherapy
Amsacrine & IDAC
Amsacrine & IDAC: Amsacrine & Intermediate Dose Ara-C (Cytarabine)
Regimen
Chemotherapy
Anastrozole and Everolimus
Regimen
Endocrine therapy
Targeted therapy
Anastrozole and Lapatinib
Regimen
Endocrine therapy
Targeted therapy
Anastrozole and Tamoxifen
Regimen
Endocrine therapy
ATRA, Cytarabine, Etoposide
Regimen
Targeted therapy
Chemotherapy
AVML
Regimen
Chemotherapy
Supportive therapy
Binimetinib monotherapy
Regimen
Targeted therapy
Bortezomib & Bevacizumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
White et al. 2012 (AMBER) | 2007-2009 | Randomized Phase 2 (E-esc) | Bortezomib | Did not meet primary endpoint of PFS (HR 0.74, 95% CI 0.43-1.28) |
Targeted therapy
Bortezomib & Siltuximab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Orlowski et al. 2015 (CR012784) | 2006-2009 | Randomized Phase 2 (E-esc) | Bortezomib | Did not meet primary endpoint of PFS (HR 0.87, 95% CI 0.65-1.16) |
Targeted therapy
Immunosuppressive therapy
BTH (Docetaxel)
BTH: Bevacizumab, Taxotere (Docetaxel), Herceptin (Trastuzumab)
Regimen
Chemotherapy
Targeted therapy
BTOC
BTOC: BCNU, Thiotepa, Oncovin (Vincristine), Cyclophosphamide
Regimen
Chemotherapy
CAD
CAD: Cyclophosphamide, Adriamycin (Doxorubicin), DDP (Cisplatin)
Regimen
Chemotherapy
Capecitabine & Cisplatin (CX) & Bevacizumab
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Cisplatin (CX) & Ramucirumab
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Ruxolitinib
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Sorafenib
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Sunitinib
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Vinflunine
Regimen
Chemotherapy
Capecitabine & Vinorelbine (NX)
NX: Navelbine (Vinorelbine) & Xeloda (Capecitabine)
Regimen
Chemotherapy
Capecitabine, Cisplatin, Cetuximab, RT
Regimen
Chemotherapy
Targeted therapy
Radiotherapy
- Concurrent radiation therapy
Capecitabine, Erlotinib, RT
Regimen
Chemotherapy
Targeted therapy
Radiotherapy
- Concurrent radiation therapy
CarboMIP
CarboMIP: Carboplatin, Mitomycin, Ifosfamide, Platinol (Cisplatin)
Regimen
Chemotherapy
Carboplatin & Epirubicin
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Bexarotene
CP & Bexarotene: Carboplatin, Paclitaxel, Bexarotene
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Cetuximab
CP & Cetuximab: Carboplatin, Paclitaxel, Cetuximab
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Erlotinib
CP & Erlotinib: Carboplatin, Paclitaxel, Erlotinib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Pegylated liposomal doxorubicin
CP & PLD: Carboplatin, Paclitaxel, Pegylated Liposomal Doxorubicin
TC & PLD: Taxol (Paclitaxel), Carboplatin, Pegylated Liposomal Doxorubicin
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Sorafenib
CP & Sorafenib: Carboplatin, Paclitaxel, Sorafenib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Topotecan
TC & Topotecan: Taxol (Paclitaxel), Carboplatin, Topotecan
Regimen
Chemotherapy
Carboplatin & Topotecan
Regimen
Chemotherapy
CBM
CBM: Capecitabine, Bevacizumab, Mitomycin
Regimen
Chemotherapy
Targeted therapy
CCG
CCG: Cisplatin, Carboplatin, Gemcitabine
Regimen
Chemotherapy
Carboplatin & Etoposide (CE) & Ipilimumab
CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
Carboplatin & Etoposide (CE) & Thalidomide
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
ChlVPP/EVA
ChlVPP/EVA: Chlorambucil, Vinblastine, Procarbazine, Prednisone alternating with Etoposide, Vincristine, Adriamycin (Doxorubicin)
Regimen
Chemotherapy, ChlVPP portion
Glucocorticoid therapy, ChlVPP portion
Chemotherapy, EVA portion
CIB
CIB: Cisplatin, Ifosfamide, Bleomycin
Regimen
Chemotherapy
Cisplatin & Gemcitabine (GC) & Erlotinib
GC & Erlotinib: Gemcitabine, Cisplatin, Erlotinib
Regimen
Chemotherapy
Targeted therapy
Cisplatin & Gemcitabine (GC) & Gefitinib
GC & Gefitinib: Gemcitabine, Cisplatin, Gefitinib
Regimen
Chemotherapy
Targeted therapy
Cisplatin & Gemcitabine (GC) & Nadroparin
GC & Nadroparin: Gemcitabine, Cisplatin, Nadroparin
Regimen
Chemotherapy
Anticoagulation
Cisplatin & Gemcitabine (GC) & Sorafenib
GC & Sorafenib: Gemcitabine, Cisplatin, Sorafenib
Regimen
Chemotherapy
Targeted therapy
Cisplatin & Gemcitabine (GC) & Tislelizumab
GC & Tislelizumab: Gemcitabine, Cisplatin, Tislelizumab
Regimen
Chemotherapy
Immunotherapy
Cisplatin & Methotrexate
Regimen
Chemotherapy
Cisplatin & Treosulfan
Regimen
Chemotherapy
Cisplatin & Vincristine
Regimen
Chemotherapy
Cisplatin, Avelumab, RT
Regimen
Chemotherapy
Immunotherapy
Radiotherapy
- Concurrent radiation therapy
Cisplatin, Pemetrexed, Gefitinib
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Soria et al. 2015 (IMPRESS) | 2012-2013 | Phase 3 (E-esc) | Cisplatin & Pemetrexed | Did not meet primary endpoint of PFS Median PFS: 5.4 vs 5.4 mo (HR 0.86, 95% CI 0.65-1.13) |
Chemotherapy
Targeted therapy
Cisplatin, Pemetrexed, RT
Regimen
Chemotherapy
Radiotherapy
- Concurrent radiation therapy
CODE
CODE: Cisplatin, Oncovin (Vincristine), Doxorubicin, Etoposide
Regimen
Chemotherapy
COPPEBVCAD
COPPEBVCAD: Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone, Epirubicin, Bleomycin, Vinblastine, CCNU (Lomustine), Alkeran (Melphalan), DVA (Vindesine)
Regimen
Chemotherapy
- Cyclophosphamide (Cytoxan)
- Vincristine (Oncovin)
- Procarbazine (Matulane)
- Epirubicin (Ellence)
- Bleomycin (Blenoxane)
- Vinblastine (Velban)
- Lomustine (CCNU)
- Melphalan (Alkeran)
- Vindesine (Eldisine)
Glucocorticoid therapy
CYVADIC
CYVADIC: CYclophosphamide, Vincristine, ADriamycin (Doxorubicin), Imidazole Carboxamide (Dacarbazine)
Regimen
Chemotherapy
DBCT
DBCT: Dacarbazine, BCNU (Carmustine), Cisplatin, Tamoxifen
Regimen
Chemotherapy
Endocrine therapy
Docetaxel & Gefitinib
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Lapatinib (TL)
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Pertuzumab
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Selumetinib
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Sunitinib
Regimen
Chemotherapy
Targeted therapy
Docetaxel & ziv-Aflibercept
Regimen
Chemotherapy
Targeted therapy
Doxorubicin & Etoposide
Regimen
Chemotherapy
Doxorubicin & Paclitaxel
Regimen
Chemotherapy
Doxorubicin & Sorafenib
Regimen
Chemotherapy
Targeted therapy
Doxorubicin & Streptozocin
Regimen
Chemotherapy
Doxorubicin & Vinblastine (AV)
AV: Adriamycin (Doxorubicin) & Vinblastine
Regimen
Chemotherapy
Doxorubicin & Vinorelbine
Regimen
Chemotherapy
EAP
EAP: Etoposide, Adriamycin (Doxorubicin), Platinol (Cisplatin)
Regimen
Chemotherapy
ECVBP
ECVBP: Epirubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
Regimen
Chemotherapy
Glucocorticoid therapy
EC-TL (Docetaxel)
EC-TL: Epirubicin & Cyclophosphamide, followed by Taxotere (Docetaxel) & Lapatinib
EC-DL: Epirubicin & Cyclophosphamide, followed by Docetaxel & Lapatinib
Regimen
Chemotherapy, EC portion
Chemotherapy, TL portion
Targeted therapy, TL portion
ELF
ELF: Etoposide, Leucovorin, 5-FU
Regimen
Chemotherapy
Encorafenib monotherapy
Regimen
Targeted therapy
EP & Ipilimumab
EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab
Regimen
Chemotherapy
Immunotherapy
EP, Tamoxifen, RT
EP, Tamoxifen, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy
Regimen
Chemotherapy
Endocrine therapy
Radiotherapy
- Concurrent thoracic radiation therapy
Erlotinib & Sunitinib
Regimen
Targeted therapy
Everolimus & Vinorelbine
Regimen
Chemotherapy
Targeted therapy
E-GEMOX
E-GEMOX: Erlotinib, GEMcitabine, OXaliplatin
Regimen
Targeted therapy
Chemotherapy
FAP
FAP: Fluorouracil, Alfa interferon, Platinol (Cisplatin)
Regimen
Chemotherapy
Immunotherapy
FEC & HP
FEC & HP: Fluorouracil, Epirubicin, Cyclophosphamide, Herceptin (Trastuzumab), Pertuzumab
Regimen
Chemotherapy
Targeted therapy
ddFEC
ddFEC: dose-dense Fluorouracil, Epirubicin, Cyclophosphamide
Regimen
Chemotherapy
Growth factor therapy
FLA
FLA: FLudarabine & Ara-C (Cytarabine)
Regimen
Chemotherapy
FLAG-Ida & GO
FLAG-Ida & GO: FLudarabine, Ara-C (Cytarabine), G-CSF (Lenograstim), Idarubicin, Gemtuzumab Ozogamicin
Regimen
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days 2 to 6
- Cytarabine (Ara-C) 2000 mg/m2 IV over 4 hours once per day on days 2 to 6, given 4 hours after fludarabine
- Idarubicin (Idamycin) 8 mg/m2 IV once per day on days 4 to 6
Growth factor therapy
Antibody-drug conjugate therapy
FLAI
FLAI: FLudarabine, Ara-C (Cytarabine), Idarubicin
FIA: Fludarabine, Idarubicin, Ara-C (Cytarabine)
Regimen
Chemotherapy
FOLF-CB
FOLF-CB: FOLinic acid, Fluorouracil, Cetuximab, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
FOLFIRI & Regorafenib
FOLFIRI & Regorafenib: FOLinic acid, Fluorouracil, IRInotecan, Regorafenib
Regimen
Chemotherapy
Targeted therapy
FOLFIRI & Simvastatin
FOLFIRI & Simvastatin: FOLinic acid, Fluorouracil, IRInotecan, Simvastatin
Regimen
Chemotherapy
Targeted therapy
FOLFIRI & Sunitinib
FOLFIRI & Sunitinib: FOLinic acid, Fluorouracil, IRInotecan, Sunitinib
Regimen
Chemotherapy
Targeted therapy
FULV & Cisplatin
FULV & Cisplatin: 5-FU & LeucoVorin (Folinic acid), Cisplatin
Regimen
Chemotherapy
FULV & Edrecolomab
FULV & Edrecolomab: 5-FU & LeucoVorin (Folinic acid), Edrecolomab
Regimen
Chemotherapy
Targeted therapy
FULV & Interferon alfa-2a
FULV & Interferon alfa-2a: 5-FU & LeucoVorin (Folinic acid), Interferon alfa-2a
Regimen
Chemotherapy
Immunotherapy
FULV & Interferon alfa-2b
FULV & Interferon alfa-2b: 5-FU & LeucoVorin (Folinic acid), Interferon alfa-2b
Regimen
Chemotherapy
Immunotherapy
FULV & Interferon alfa-2c
FULV & Interferon alfa-2c: 5-FU & LeucoVorin (Folinic acid), Interferon alfa-2c
Regimen
Chemotherapy
Immunotherapy
FULV & Trimetrexate
FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate
Regimen
Chemotherapy
GVP
GVP: Gemcitabine, Vinorelbine, Platinol (Cisplatin)
Regimen
Chemotherapy
ICE, ATRA, GO
ICE, ATRA, GO: Idarubicin, Cytarabine, Etoposide, All-Trans Retinoic Acid, Gemtuzumab Ozogamicin
Regimen
Chemotherapy
Targeted therapy
Antibody-drug conjugate therapy
Ixabepilone & Bevacizumab
Regimen
Chemotherapy
Targeted therapy
ME
ME: Mitoxantrone & Etoposide
Regimen
Chemotherapy
MEV
MEV: Mitomycin, Etoposide, Vindesine
Regimen
Chemotherapy
MFL
MFL: Methyl-lomustine (MeCCNU), 5-FU, Leucovorin (Folinic acid)
Regimen
Chemotherapy
MFT
MFL: Methotrexate, 5-FU, Tamoxifen
Regimen
Chemotherapy
Endocrine therapy
Mitoxantrone & Hydrocortisone
Regimen
Chemotherapy
Endocrine therapy
MMF
MMF: Methyl-lomustine (MeCCNU), Mitomycin, 5-FU
Regimen
Chemotherapy
MOPPEBVCAD
MOPPEBVCAD: Mechlorethamine, Oncovin (Vincristine), Procarbazine, Prednisone, Epirubicin, Bleomycin, Vinblastine, CCNU (Lomustine), Adriamycin (Doxorubicin), DVA (Vindesine)
Regimen
Chemotherapy
- Mechlorethamine (Mustargen)
- Vincristine (Oncovin)
- Procarbazine (Matulane)
- Epirubicin (Ellence)
- Bleomycin (Blenoxane)
- Vinblastine (Velban)
- Lomustine (CCNU)
- Doxorubicin (Adriamycin)
- Vindesine (Eldisine)
Glucocorticoid therapy
MPP
MPP: Melphalan, Prednisone, Procarbazine
Regimen
Chemotherapy
Glucocorticoid therapy
MTP
MTP: Myocet (Non-pegylated liposomal doxorubicin), Trastuzumab, Paclitaxel
Regimen
Chemotherapy
Targeted therapy
MVC
MVC: Mitomycin, Vindesine, Carboplatin
Regimen
Chemotherapy
NIP
NIP: Navelbine (Vinorelbine), Ifosfamide, Platinol (Cisplatin)
Regimen
Chemotherapy
Neratinib & Paclitaxel
Regimen
Targeted therapy
Chemotherapy
PD & Pembrolizumab
PD & Pembrolizumab: Pomalidomide, Dexamethasone, Pembrolizumab
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Mateos et al. 2019 (KEYNOTE-183) | 2016-2017 | Phase 3 (E-esc) | PD | Seems to have inferior PFS (HR 1.53, 95% CI 1.05-2.22) |
Targeted therapy
Glucocorticoid therapy
Immunotherapy
PEI
PEI: Platinol (Cisplatin), Etoposide, Ifosfamide
Regimen
Chemotherapy
PELF
PELF: Platinol (Cisplatin), Epirubicin, Leucovorin, 5-FU
Regimen
Chemotherapy
PGT
PGT: Platinol (Cisplatin), Gemcitabine, Taxol (Paclitaxel)
Regimen
Chemotherapy
PGV
PGV: Platinol (Cisplatin), Gemcitabine, Vinorelbine
CGV: Cisplatin, Gemcitabine, Vinorelbine
Regimen
Chemotherapy
Pemetrexed & Cetuximab
Regimen
Chemotherapy
Targeted therapy
Pemetrexed & Vandetanib
Regimen
Chemotherapy
Targeted therapy
Pixantrone & Rituximab
Regimen
Chemotherapy
Targeted therapy
PVI
PVI: Platinol (Cisplatin), Vindesine, Ifosfamide
VIP: Vindesine, Ifosfamide, Platinol (Cisplatin)
Regimen
Chemotherapy
R-BEACOPP
R-BEACOPP: Rituximab, Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone
Regimen
Targeted therapy
Chemotherapy
- Bleomycin (Blenoxane)
- Etoposide (Vepesid)
- Doxorubicin (Adriamycin)
- Cyclophosphamide (Cytoxan)
- Vincristine (Oncovin)
- Procarbazine (Matulane)
Glucocorticoid therapy
R-MegaCHOEP
R-MegaCHOEP: Rituximab, high-dose (Mega) Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Etoposide, Prednisone
Targeted therapy
Chemotherapy
Glucocorticoid therapy
Realgar-Indigo naturalis formulation monotherapy
Regimen
Targeted therapy
TCG
TCG: Taxol (Paclitaxel), Carboplatin, Gemcitabine
Regimen
Chemotherapy
TCHL (Docetaxel)
TCHL: Taxotere (Docetaxel), Carboplatin, Herceptin (Trastuzumab), Lapatinib
Regimen
Chemotherapy
Targeted therapy
TCL (Docetaxel)
TCL: Taxotere (Docetaxel), Carboplatin, Lapatinib
Regimen
Chemotherapy
Targeted therapy
TEC
TEC: Taxol (Paclitaxel), Epirubicin, Carboplatin
Regimen
Chemotherapy
Paclitaxel & Trastuzumab (TH) & Everolimus
TH & Everolimus: Taxol (Paclitaxel), Herceptin (Trastuzumab), Everolimus
Regimen
Chemotherapy
Targeted therapy
TPCV
TPCV: Thioguanine, Procarbazine, CCNU, Vincristine
Regimen
Chemotherapy
VADx
VADx: Vincristine, Ara-C (Cytarabine), Dexamethasone
Regimen
Chemotherapy
Glucocorticoid therapy
VAPEC-B
VAPEC-B: Vincristine, Adriamycin (Doxorubicin), Prednisolone, Etoposide, Cyclophosphamide, Bleomycin
Regimen
Chemotherapy
- Vincristine (Oncovin)
- Doxorubicin (Adriamycin)
- Etoposide (Vepesid)
- Cyclophosphamide (Cytoxan)
- Bleomycin (Blenoxane)
Glucocorticoid therapy
VBM (Vinblastine)
VBM: Vinblastine, Bleomycin, Methotrexate
Regimen
Chemotherapy
VCE
VCE: Vincristine, Carboplatin, Etoposide
Regimen
Chemotherapy
Vinorelbine & Hydrocortisone
Regimen
Chemotherapy
Endocrine therapy
VNC
VNC: Vincristine, Novantrone (Mitoxantrone), Cyclophosphamide
Regimen
Chemotherapy
VPV
VPV: Vinblastine, Platinol (Cisplatin), VP-16 (Etoposide)
Regimen
Chemotherapy
VTDC
VTDC: Velcade (Bortezomib), Thalidomide, Dexamethasone, Cyclophosphamide
Regimen
Targeted therapy
Glucocorticoid therapy
Chemotherapy
Regimens that contain experimental (unapproved) drugs
Adavosertib & Gemcitabine
Regimen
Targeted therapy
Chemotherapy
Alisertib monotherapy
Regimen
Targeted therapy
Amonafide & Cytarabine
Regimen
Chemotherapy
Buparlisib & Fulvestrant
Regimen
Targeted therapy
Endocrine therapy
Buparlisib & Paclitaxel
Regimen
Targeted therapy
Chemotherapy
Carboplatin & Paclitaxel (CP) & Agatolimod
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & BMS-275291
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Cediranib
CP & Cediranib: Carboplatin, Paclitaxel, Cediranib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Farletuzumab
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Figitumumab
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Motesanib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Tirapazamine
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Trebananib
TC & Trebananib: Taxol (Paclitaxel), Carboplatin, Trebananib
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Vergote et al. 2019 (TRINOVA-3) | 2012-2014 | Phase 3 (E-esc) | TC | Did not meet primary endpoint of PFS (HR 0.93, 95% CI 0.79-1.09) |
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Vadimezan
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Veliparib
CP & Veliparib: Carboplatin, Paclitaxel, Veliparib
Regimen
Chemotherapy
Targeted therapy
Cediranib monotherapy
Regimen
Targeted therapy
Docetaxel & Bavituximab
Regimen
Chemotherapy
Immunotherapy
Docetaxel & Ganetespib
Regimen
Chemotherapy
Targeted therapy
Erlotinib & Figitumumab
Regimen
Targeted therapy
Erlotinib & Onartuzumab
Regimen
Targeted therapy
Erlotinib & Tivantinib
Regimen
Targeted therapy
Cisplatin & Gemcitabine (GC) & Veliparib
GC & Veliparib: Gemcitabine, Cisplatin, Veliparib
Regimen
Chemotherapy
Targeted therapy
Ibrutinib & Ublituximab
Regimen
Targeted therapy
Pegylated liposomal doxorubicin & Trebananib
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Marth et al. 2016 (TRINOVA-2) | 2011-2013 | Phase 3 (E-esc) | PLD | Did not meet primary endpoint of PFS (HR 0.92, 95% CI 0.68-1.24) |